ClinicalTrials.gg
Not yet recruitingNCT07849855SARME-TBA/HAUpdated Sep 30, 2026

Tooth-Borne (TBA) Versus Hybrid Expanders (HA) in Surgically Assisted Rapid Maxillary Expansion (SARME)

An interventional study of Tooth-Borne Maxillary Expansion Appliance and Hybrid Tooth-Bone-Borne Maxillary Expansion Appliance in Maxillary Transverse Deficiency, sponsored by Aalborg University Hospital. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Aalborg University Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized clinical trial will compare two types of expansion appliances used with surgically assisted rapid maxillary expansion (SARME) in adults with a narrow upper jaw. SARME is a surgical and orthodontic treatment used to widen the upper jaw when orthodontic expansion alone is not sufficient. The study will investigate whether a tooth-borne appliance, which is supported by the teeth, and a hybrid appliance, which is supported by both the teeth and two small screws placed in the palate, produce different treatment outcomes.

A total of 32 adults scheduled for SARME at Aalborg University Hospital in Denmark and Lund University Hospital in Sweden will be randomly assigned to treatment with either the tooth-borne appliance or the hybrid appliance. Participants will be examined before surgery, after completion of the expansion phase, and six months after completion of expansion. Assessments will include cone-beam computed tomography (CBCT), digital dental scans, facial imaging, periodontal examinations, recording of complications, and questionnaires about pain, recovery, oral health-related quality of life, general quality of life, and treatment experience.

The main outcome of the study is skeletal relapse, meaning how much of the widening of the upper jaw is lost between the end of expansion and the six-month follow-up. Other outcomes include the amount of skeletal and dental expansion, tooth tipping, changes in the supporting bone and gums around the teeth, facial soft-tissue changes, complications, recovery, and patient-reported quality of life. The study aims to determine whether one appliance provides better stability or fewer unwanted effects and thereby improve future treatment recommendations for adults undergoing SARME.

Read the detailed description

Maxillary transverse deficiency in skeletally mature patients may require surgically assisted rapid maxillary expansion (SARME) when the transverse discrepancy cannot be predictably corrected by orthodontic expansion alone. Tooth-borne appliances (TBA) have traditionally been used for SARME; however, transmission of expansion forces through the teeth may contribute to dental tipping, bending of the alveolar process, periodontal effects, and subsequent dental or skeletal relapse. Hybrid appliances (HA) combine dental anchorage with skeletal anchorage through palatal mini-implants, thereby distributing part of the expansion force directly to the maxillary bone. This may potentially improve skeletal stability and reduce unwanted dentoalveolar effects. However, comparative randomized evidence using standardized three-dimensional assessments and patient-reported outcomes remains limited.

This is a two-centre, two-arm, parallel-group randomized controlled trial conducted at the Departments of Oral and Maxillofacial Surgery at Aalborg University Hospital, Denmark, and Lund University Hospital, Sweden. Thirty-two adults scheduled for SARME will be randomized in a 1:1 ratio to treatment with either TBA or HA. Computer-generated block randomization will be stratified by study centre, with allocation concealed using sequentially numbered sealed envelopes. The surgical procedure, postoperative distraction protocol, and consolidation period will be standardized between the treatment groups and study centres.

Study assessments will be performed at baseline before surgery (T0), at the end of the distraction phase (T1), and six months after completion of expansion following the consolidation period (T2). The study uses a multimodal three-dimensional assessment strategy incorporating cone-beam computed tomography, digital intraoral models, standardized three-dimensional facial stereophotography, periodontal examination, complication registration, and validated self-administered patient-reported outcome measures.

The study is designed to determine whether partial skeletal anchorage with a hybrid appliance produces clinically meaningful differences in transverse skeletal stability compared with conventional tooth-borne anchorage. The investigation will also provide a comprehensive assessment of dentoalveolar, periodontal, facial soft-tissue, complication-related, recovery-related, and patient-reported effects associated with the two appliance concepts.

Measurements will be performed using coded datasets and standardized measurement protocols. The primary statistical analysis will follow the intention-to-treat principle. Repeated measurements will be analysed using linear mixed-effects models accounting for treatment group, time, and repeated observations within participants. Statistical analyses will be performed without knowledge of treatment allocation where feasible.

02

Conditions studied

  • Maxillary Transverse Deficiency

Keywords

  • Surgically Assisted Rapid Maxillary Expansion
  • SARME
  • Surgically Assisted Rapid Palatal Expansion
  • SARPE
  • Tooth-Borne Appliance
  • Hybrid Appliance
  • Skeletal Anchorage
  • Maxillary Expansion
  • Skeletal Relapse
  • Dentoalveolar Expansion
  • Cone-Beam Computed Tomography
  • CBCT
03

In context

Lead sponsor

Aalborg University Hospital is the lead sponsor of 199 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate or severe maxillary transverse deficiency (MTD).
  • Healthy adults aged 18 years or older.
  • Completed craniofacial growth.
  • Presence of the maxillary first premolars and first molars.
  • Healthy periodontal status.

Exclusion criteria

Exclusion Criteria:

  • Previous surgical treatment of facial trauma or dentofacial deformities.
  • Systemic disease, medication, genetic disease, or developmental condition expected to affect craniofacial morphology, bone turnover, or healing.
  • Pregnancy.
  • Inability to understand the study information or provide written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Active comparator
    Tooth-Borne Appliance (TBA)

    Participants allocated to this arm will undergo surgically assisted rapid maxillary expansion (SARME) using a tooth-borne appliance (TBA). The computer-aided design/computer-aided manufacturing (CAD/CAM)-fabricated appliance consists of four printed metal bands cemented to the maxillary first premolars and first molars and connected to a palatal expansion mechanism. No palatal mini-implants are used. The appliance is cemented before surgery. Following SARME, expansion is initiated after a latency period of 5-7 days at approximately 0.5 mm/day until the planned expansion or overcorrection is achieved. The appliance is then maintained passively during a six-month consolidation period.

    Device: Tooth-Borne Maxillary Expansion Appliance

  • Experimental
    Hybrid Appliance (HA)

    Participants allocated to this arm will undergo surgically assisted rapid maxillary expansion (SARME) using a hybrid appliance (HA). The appliance uses the same CAD/CAM design as the tooth-borne appliance, with four printed metal bands on the maxillary first premolars and first molars connected to a palatal expansion mechanism. In addition, skeletal anchorage is provided by two palatal mini-implants (BENEfit® DIRECT screws, 2.0 mm diameter, 9 mm length), inserted immediately before surgery under general anaesthesia and connected to the expander. Following SARME, expansion is initiated after a latency period of 5-7 days at approximately 0.5 mm/day until the planned expansion or overcorrection is achieved. The appliance is then maintained passively during a six-month consolidation period.

    Device: Hybrid Tooth-Bone-Borne Maxillary Expansion Appliance

Interventions

  • DeviceTooth-Borne Maxillary Expansion Appliance

    A CAD/CAM-fabricated tooth-borne maxillary expansion appliance used during surgically assisted rapid maxillary expansion (SARME). The appliance consists of four printed metal bands cemented to the maxillary first premolars and first molars and connected to a palatal expansion mechanism. Anchorage is provided exclusively by the teeth, with no palatal mini-implants. The appliance is cemented before surgery. Following a postoperative latency period of 5-7 days, the appliance is activated at approximately 0.5 mm per day until the planned expansion or clinical overcorrection is achieved. The appliance is subsequently maintained passively during the six-month consolidation period.

    Also known as: Tooth-Borne Appliance, TBA

  • DeviceHybrid Tooth-Bone-Borne Maxillary Expansion Appliance

    A CAD/CAM-fabricated hybrid tooth-bone-borne maxillary expansion appliance used during surgically assisted rapid maxillary expansion (SARME). The appliance consists of four printed metal bands on the maxillary first premolars and first molars connected to a palatal expansion mechanism. In addition to dental anchorage, skeletal anchorage is provided by two palatal mini-implants (BENEfit® DIRECT screws, 2.0 mm diameter and 9 mm length) inserted immediately before surgery and connected to the expander. Following a postoperative latency period of 5-7 days, the appliance is activated at approximately 0.5 mm per day until the planned expansion or clinical overcorrection is achieved, followed by a six-month passive consolidation period.

    Also known as: Hybrid Appliance, HA

06

What researchers measure

Primary outcomes

  1. Transverse Skeletal Relapse in External Maxillary Width

    Transverse skeletal relapse will be assessed as the reduction in external maxillary width (EMW) from the end of the distraction phase (T1) to the six-month follow-up (T2). EMW will be measured in millimetres on CBCT images at the maxillary first premolar and first molar levels, using the hard palate as the skeletal reference. Skeletal relapse will be calculated as the T1 EMW minus the T2 EMW; a larger positive value indicates greater skeletal relapse.

    Time frame: From the end of the distraction phase to 6 months after completion of expansion

Secondary outcomes

  1. Change in External Maxillary Width During Expansion

    Change in external maxillary width (EMW) from baseline (T0) to the end of the distraction phase (T1). EMW will be measured in millimetres on CBCT images at the maxillary first premolar and first molar levels, using the hard palate as the skeletal reference.

    Time frame: From baseline before surgery to the end of the distraction phase, approximately 15-30 days after surgery

  2. Change in Maxillary Dental Arch Width

    Maxillary transverse dental width will be measured in millimetres using digital dental models and/or CBCT-derived dental landmarks. Measurements include intercanine width (cusp tip to cusp tip), interpremolar width at the first premolars (buccal cusp tip to buccal cusp tip), and intermolar width at the first molars (mesiobuccal cusp tip to mesiobuccal cusp tip). Changes between T0, T1, and T2 will be calculated to assess expansion and subsequent dental relapse.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  3. Change in Maxillary Tooth Inclination

    Change in inclination of the maxillary canines, first premolars, and first molars will be measured in degrees on standardized coronal CBCT images. Tooth inclination will be determined using predefined crown and root landmarks, and angular changes between study timepoints will be calculated.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  4. Plaque Index

    Periodontal plaque accumulation will be assessed using the Plaque Index according to the standardized periodontal examination protocol. Measurements will be obtained at predefined sites around selected maxillary teeth, with corresponding mandibular teeth assessed as controls.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  5. Change in Gingival Index

    Gingival inflammation will be assessed using the Gingival Index according to the standardized periodontal examination protocol at predefined sites around selected maxillary teeth, with corresponding mandibular teeth assessed as controls.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  6. Change in Periodontal Probing Pocket Depth

    Probing pocket depth will be measured in millimetres at six periodontal sites per selected tooth: mesiobuccal, mid-buccal, distobuccal, mesiolingual, mid-lingual, and distolingual. Measurements will be performed at selected maxillary teeth with corresponding mandibular teeth serving as controls.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  7. Change in Clinical Attachment Level

    Clinical attachment level will be measured in millimetres at standardized periodontal sites around selected maxillary teeth, with corresponding mandibular teeth assessed as controls.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  8. Change in Buccal Alveolar Bone Thickness and Height

    Buccal alveolar bone thickness and height around the teeth supporting the expansion appliance will be assessed in millimetres using standardized CBCT measurements. Changes between T0, T1, and T2 will be used to assess alveolar bone effects associated with the two expansion appliances.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  9. Change in Three-Dimensional Facial Soft-Tissue Measurements

    Standardized three-dimensional stereophotogrammetry will be used to assess facial soft-tissue changes. Prespecified measurements include nasal base width, alar base width, nasal tip protrusion, paranasal soft-tissue changes, upper-lip region changes, facial asymmetry, and regional surface displacement. Changes between T0, T1, and T2 will be assessed using reconstructed 3D facial models.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  10. Incidence of Surgical and Appliance-Related Complications

    The number and type of intraoperative, postoperative, and appliance-related complications will be recorded prospectively in the case report form. Events include bleeding, infection, wound dehiscence, neurosensory disturbance, asymmetric or inadequate expansion, appliance loosening or fracture, cement or band failure, expansion screw malfunction, soft-tissue irritation or ulceration, and miniscrew-related complications in the hybrid appliance group.

    Time frame: From surgery through 6 months after completion of expansion

  11. Change in Oral Health Impact Profile-14 (OHIP-14) Score

    Oral health-related quality of life will be assessed using the 14-item Oral Health Impact Profile (OHIP-14). The total score ranges from 0 to 56, with higher scores indicating poorer oral health-related quality of life.

    Time frame: Baseline before surgery, one week after surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  12. Change in Short Form-36 Health Survey (SF-36) Scores

    General health-related quality of life will be assessed using the 36-item SF-36 questionnaire. The instrument evaluates physical functioning, physical health limitations, emotional problems, energy/fatigue, emotional well-being, social functioning, bodily pain, and general health. Scores are transformed to a 0-100 scale, with higher scores indicating better health status.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  13. Postoperative Pain Intensity Assessed by Visual Analogue Scale

    Postoperative pain intensity will be recorded using a self-administered pain diary and a 100-mm visual analogue scale (VAS), where 0 mm represents no pain and 100 mm represents the worst tolerable pain. Pain will be recorded immediately before and one hour after analgesic intake. Analgesic consumption, including additional analgesic use, will also be documented.

    Time frame: During the first 15 postoperative days

  14. Quality of Recovery-15 (QoR-15) Score

    Early postoperative recovery will be assessed using the validated 15-item Quality of Recovery questionnaire (QoR-15), covering pain, physical comfort, physical independence, emotional state, and psychological support. The total score ranges from 0 to 150, with higher scores indicating better postoperative recovery.

    Time frame: Postoperative day 1 and postoperative day 7

  15. Patient-Reported Recovery After SARME

    Patient perception of recovery will be assessed using a self-administered recovery questionnaire. Prespecified domains include duration of pain, sick leave, effects on work and usual activities, physical and social activity, eating and chewing ability, dietary changes, speech, sleep, quality of life, and treatment satisfaction. Responses include yes/no items, Likert-type responses, visual analogue scales, and number of affected days.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  16. Change in Clinical Nasal Deviation

    Clinical nasal deviation will be assessed from standardized frontal facial photographs. Photographs obtained at T1 and T2 will be superimposed on the baseline T0 photograph after standardization of magnification. Nasal deviation will be quantified as the angular change in the columella/facial midline reference relative to the reference line between the medial palpebral commissures. Greater angular change indicates greater deviation from the baseline nasal position.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  17. Change in Radiographic Nasal Septum Deviation

    Radiographic nasal septum deviation will be assessed using standardized coronal CBCT images. Images will be compared by superimposing T1 and T2 images with the baseline T0 image, with standardized magnification and orientation. Changes will be assessed for T0 to T1, T0 to T2, and T1 to T2 to evaluate whether maxillary expansion is associated with changes in nasal septum position.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

Other outcomes

  1. Change in Midpalatal Sutural Expansion Width

    Midpalatal sutural expansion width will be measured in millimetres on axial CBCT images at the incisor, canine, first premolar, and first molar levels. Changes between T0, T1, and T2 will be calculated to characterize sutural opening during the distraction phase and subsequent change during the consolidation period.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

  2. Change in Maxillary Midline Diastema Width

    The width of the midline diastema between the maxillary central incisors will be measured in millimetres on digital dental models obtained from standardized intraoral scans. Measurements at T0, T1, and T2 will be compared to assess development of the diastema during expansion and subsequent change during consolidation.

    Time frame: Baseline before surgery, end of the distraction phase approximately 15-30 days after surgery, and 6 months after completion of expansion

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available because the study involves sensitive clinical and radiographic data collected at two hospital sites and will be handled in accordance with applicable data-protection requirements and the approved study protocol. Study results will be reported in aggregated or appropriately anonymized form in scientific publications and presentations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2031, 59 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 30, 2026
StartEst.
Jan 2027
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2031
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849855
Collaborators
Lund University Hospital
Responsible party
Osman Khachab (Specialist Orthodontist, Aalborg University Hospital) — Principal investigator
First posted
Sep 30, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Sep 30, 2026

Study contacts

Osman Khachab, DDs, MSc
Contact
osmankhachab@gmail.com
+46 720441061
Thomas Starch-Jensen, Professor
study director · Aalborg University Hospital
Hanna Hejlesen, PhD, Head of department
study chair · Aalborg University Hospital
Martin Bengtsson, Associate Professor
study chair · Skane University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion